SCHEMBL2436664

SCHEMBL2436664

Nc1ccccc1-c1cc(=O)c2ccccc2o1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 5/20 0.67
▸ NPC1 O15118 5/20 0.67
▸ RAB9A P51151 4/20 0.67
▸ SMN1; SMN2 Q16637 4/20 0.67
▸ AKR1C3 P42330 1/20 0.67
▸ AKR1C2 P52895 1/20 0.67
▸ AKR1C1 Q04828 1/20 0.67
▸ CYP3A4 P08684 4/20 0.62
▸ TP53 P04637 3/20 0.62
▸ MEN1 O00255 3/20 0.62
▸ CYP2C9 P11712 3/20 0.62
▸ CYP2C19 P33261 3/20 0.62
▸ KMT2A Q03164 3/20 0.62
▸ ALDH1A1 P00352 3/20 0.62
▸ CYP2D6 P10635 2/20 0.62
▸ MAPT P10636 2/20 0.62
▸ ALOX15 P16050 2/20 0.62
▸ GMNN O75496 1/20 0.62
▸ RAF1 P04049 1/20 0.62
▸ CYP1A2 P05177 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10432657 0.83 ESR1 (0.61) HPGDNPC1RAB9ASMN1; SMN2AKR1C3
SCHEMBL311714 0.83 HPGD (0.76) HPGDNPC1RAB9ASMN1; SMN2AKR1C3
SCHEMBL22806648 0.83 HPGD (0.72) HPGDNPC1RAB9ASMN1; SMN2AKR1C3
SCHEMBL4634256 0.81 HPGD (0.73) HPGDNPC1RAB9ASMN1; SMN2AKR1C3
SCHEMBL9284336 0.80 HPGD (0.70) HPGDNPC1RAB9ASMN1; SMN2AKR1C3
SCHEMBL25186939 0.80 HPGD (0.67) HPGDNPC1RAB9ASMN1; SMN2AKR1C3
SCHEMBL3205778 0.80 HPGD (0.67) HPGDNPC1RAB9ASMN1; SMN2AKR1C3
SCHEMBL312255 0.80 AKR1C3 (1.00) HPGDNPC1RAB9ASMN1; SMN2AKR1C3
SCHEMBL87773 0.80 HPGD (0.67) HPGDNPC1RAB9ASMN1; SMN2AKR1C3
SCHEMBL1423180 0.80 HPGD (0.67) HPGDNPC1RAB9ASMN1; SMN2AKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1996031206-A2 FLAVONES AND COUMARINS AS AGENTS FOR THE TREATMENT OF ATHEROSCLEROSIS WARNER-LAMBERT COMPANY (US) 1996-10-10 — — WO claimed
WO-2011106373-A2 ARNT ISOFORM 3 AS A PREDICTOR OF AMINOFLAVONE RESPONSIVENESS IN CANCER CELLS UNIVERSITY OF MARYLAND, BALTIMORE (US) 2011-09-01 — — WO disclosed
WO-1996031206-A2 FLAVONES AND COUMARINS AS AGENTS FOR THE TREATMENT OF ATHEROSCLEROSIS WARNER-LAMBERT COMPANY (US) 1996-10-10 — — WO disclosed
Send feedback